应用聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者血清sVAP-1和SAA水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2023.04.008

Abstract

Abstract: Objective The aim of this study was to explore the implication of serum soluble vascular adhesion protein-1 (sVAP-1) and serum amyloid A (SAA) levels in patients with chronic hepatitis C (CHC) receiving pegylated interferon α-2a (peg-IFN-α-2a) and ribavirin standardized treatment. Methods 62 patients with CHC and 48 healthy persons were enrolled in our hospital between February 2018 and February 2022, and all patients with CHC were treated with peg-IFN α-2a and ribavirin for 24 weeks. Serum sVAP-1 and SAA levels were detected by ELISA, and serum HCV RNA load was detected by real-time fluorescence quantitative PCR. The virologic response was evaluated by early virologic response (EVR), end treatment virologic response (ETVR) and sustained virologic response (SVR). Results Serum sVAP-1 and SAA levels in patients with CHC were (164.0±29.3)μg/L and (3.0±0.6)mg/L, significantly higher than [(73.7±15.8)μg/L and (0.8±0.2)mg/L, P<0.05] in healthy persons; serum sVAP-1 and SAA levels in 17 CHC patients with high serum viral loads were (225.9±33.7)μg/L and (4.3±0.7) mg/L, significantly higher than [(156.7±28.4)μg/L and (3.0±0.5)mg/L, respectively, P<0.05] in 26 CHC patients with medium viral loads or [(118.7±22.0)μg/L and (1.8±0.3)mg/L, respectively, P<0.05] in 19 CHC patients with low viral loads; serum SAA levels in patients who responded to antiviral therapy were significantly higher than non-responders [EVR:(4.1±0.7)mg/L vs. (2.2±0.5)mg/L; ETVR:(3.2±0.9)mg/L vs. (1.6±0.4)mg/L and SVR:(3.7±0.8)mg/L vs.(1.5±0.4)mg/L, P<0.05], while there were no significant differences as respect to serum sVAP-1 levels between responders and non-responders (P>0.05). Conclusion Serum sVAP-1 and SAA levels in patients with CHC increase, and their changes are related to virus replication. It might be helpful by monitoring serum SAA level changes in predicting the antiviral efficacy in patients with CHC.

Key words: Hepatitis C, Pegylated interferon α-2a, Ribavirin, Soluble vascular adhesion protein-1, Serum amyloid A, Therapy, Response

Yang Kai, Zhang Kai, Wang Yong. Implication of serum sVAP-1 and SAA levels in patients with chronic hepatitis C receiving pegylated interferon α-2a and ribavirin standardized treatment[J]. Journal of Practical Hepatology, 2023, 26(4): 484-487.

References

[1] 揭育胜, 袁静, 张晓红,等. 奥比帕利联合达塞布韦用于中国基因1b型丙型肝炎病毒慢性感染的真实世界研究. 中华肝脏病杂志, 2019, 27(2):123-127.
[2] Zheng Z, Sze CW, Keng CT, et al. Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS One, 2017, 12(9):e0184127.
[3] Naggie S. Hepatitis C virus, inflammation, and cellular aging: turning back time. Top Antivir Med, 2017, 25(1):3-6.
[4] Kurkijärvi R, Yegutkin GG, Gunson BK, et al. Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology, 2000, 119(4):1096-1103.
[5] Lalor PF, Sun PJ, Weston CJ, et al. Activation of vascular adhesion protein-1 on liver endothelium results in an NF-kappaB-dependent increase in lymphocyte adhesion. Hepatology, 2007, 45(2):465-474.
[6] 赵昕峰, 吴亦栋, 高扬,等. 血清淀粉样蛋白A联合C反应蛋白检测在手足口病患儿中的诊断价值. 中华传染病杂志, 2016, 34(7):419-421.
[7] Lannergard A, Larsson A, Kragsbjerg P, et al. Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scand J Clin Lab Invest, 2003, 63(4):267-272.
[8] Lavie M, Voisset C, Vu-Dac N, et al. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology, 2006, 44(6):1626-1634.
[9] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙?透窝追乐沃改?2019年版). 实用肝脏病杂志, 2020, 23(1):33-52.
[10] 何涛君, 杨来智, 吴润香,等. 102例慢性丙型肝炎患者血清免疫球蛋白和补体水平变化. 实用肝脏病杂志, 2015, 18(5):538-539.
[11] 徐欢, 王广丽, 董丹丹,等. 聚乙二醇干扰素α-2a联合利巴韦林标准抗病毒治疗慢性丙型肝炎患者疗效再研究. 实用肝脏病杂志, 2022, 25(4):500-503.
[12] Kuo CH, Wei JN, Yang CY, et al. Serum vascular adhesion protein-1 is up-regulated in hyperglycemia and is associated with incident diabetes negatively. Int J Obes (Lond), 2019, 43(3):512-522.
[13] Noonan T, Lukas S, Peet GW, et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am J Clin Exp Immunol, 2013, 2(2):172-185.
[14] Ma Q, Manaenko A, Khatibi NH, et al. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J Cereb Blood Flow Metab, 2011, 31(3):881-893.
[15] 顾敏晔, 顾国浩, 石亚玲,等. 血清淀粉样蛋白A在新型冠状病毒肺炎诊疗中的应用价值. 中华检验医学杂志, 2020, 43(9):935-938.
[16] 赵海潇, 刘伟贤, 周丽. 血清淀粉样蛋白A在刀豆球蛋白A诱导肝损伤中的作用. 中华实验外科杂志, 2017, 34(12):2132-2134.
[17] Kjellmo CA, Karlsson H, Nestvold TK, et al. Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity. J Clin Lipidol, 2018, 12(1):193-202.
[18] Hari-Dass R, Shah C, Meyer DJ, et al. Serum amyloid A protein binds to outer membrane protein A of gram-negative bacteria. J Biol Chem, 2005, 280(19):18562-18567.
[19] 孟海妹, 魏蔚, 焦亚冲,等. 血清淀粉样蛋白A通过Toll样受体4途径诱导类风湿关节炎中性粒细胞胞外诱捕网形成. 中华风湿病学杂志, 2017, 21(6):404-408.
[20] 沈方方, 薛海燕, 曹兰芳. 血清淀粉样蛋白A在鉴别全身型幼年特发性关节炎患儿活动与感染中的意义. 中华全科医师杂志, 2019, 18(1):61-64.
[21] Lee JY, Hall JA, Kroehling L, et al. Serum amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell, 2020, 180(1):79-91.
[22] 李明遥, 白云强, 刘毅. 系统性红斑狼疮患者血清基质金属蛋白酶-3水平及其在鉴别疾病活动与合并肺部感染的意义. 中华内科杂志, 2020, 59(1):58-61.
[23] Sorić Hosman I, Kos I, Lamot L. Serum amyloid A in inflammatory rheumatic diseases: a compendious review of a renowned biomarker. Front Immunol, 2021, 11:631299.
[24] Gschwantler M, Dulic M, Dulic-Lakovic E, et al. Increased levels of serum amyloid A during the early phase of hepatitis C treatment with interferon are associated with sustained virologic response - a pilot study. J Gastrointestin Liver Dis, 2014, 23(1):101-102.

Implication of serum sVAP-1 and SAA levels in patients with chronic hepatitis C receiving pegylated interferon α-2a and ribavirin standardized treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Zhuoya, Wu Yangpeng, Huang Yitao. Observation of polyene phosphatidylcholine and zhibitai capsule combination in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 496-499.
[2]	Zhen Yongli , Zhang Yafei , Zhang Zhenhua. Changes of thyroid hormone in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 508-511.
[3]	Tang Xinhua, Tang Huijing, Huang Chengjun, et al. Preventive effect of entecavir on anti-tuberculosis drug-induced liver injury in patients with pulmonary tuberculosis and serum HBeAg-positive high HBV loads [J]. Journal of Practical Hepatology, 2023, 26(4): 516-519.
[4]	Ding Shanshan, Ding Kai, Jiang Ning. Sofosbuvir/velpatasvir plus ribavirin for patients with compensated and decompensated hepatitis C liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(4): 536-539.
[5]	Yuan Xiaobing, Chen Weiwei, Liu Xiaoli, et al. Implications of peripheral blood natural killer cell percentages in patients with hepatocellular carcinoma after radical hepatectomy [J]. Journal of Practical Hepatology, 2023, 26(4): 544-547.
[6]	Zhu Jiameng, Fan Liqin, Yin Li, et al. Laparoscopic hepatectomy in the treatment of patients with giant hepatic hemangioma [J]. Journal of Practical Hepatology, 2023, 26(4): 564-567.
[7]	Huang Yu, Wang Zhuo, Ren Chenggang, et al. Laparoscopic cholecystectomy,shortly or a little longer after PTGD in the treatment of patients with acute calculous cholecystitis? [J]. Journal of Practical Hepatology, 2023, 26(4): 568-571.
[8]	Zeng Lin, Zhang Yong, Luo Jiubao, et al. Could herbal medicine,Shuli Tongxie Decoction, decrease the relapse of stones in patients with chronic cholecystitis and cholelithiasis after laparoscopic cholecystectomy? [J]. Journal of Practical Hepatology, 2023, 26(4): 572-575.
[9]	Liu Zejun, Mu Haifeng, Chen Shengbao, et al. Immediate laparoscopic cholecystectomy and laparoscopic common bile duct exploration in treatment of patients with simultaneous cholecystolithiasis and choledocholithiasis [J]. Journal of Practical Hepatology, 2023, 26(4): 576-579.
[10]	Zheng Feng, Li Yanrong, Luo Weijun, et al. Is the gallbladder posterior triangle approach superior to triangle approach during laparoscopic cholecystectomy in treatment of patients with gallbladder stones and chronic cholecystitis? [J]. Journal of Practical Hepatology, 2023, 26(4): 580-583.
[11]	Zhou Hongfei, Chen Zhong, Gu Hong, et al. Convenient clearance of recurred stone in patients with hepatolithiasis undergoing Roux-en-Y choledochojejunostomyand subcutaneous buried blind jejunal loop [J]. Journal of Practical Hepatology, 2023, 26(4): 584-587.
[12]	Zhang Danlei, Xu Jing. Early antiviral efficacy of tenofovir amibufenamide in treatment of naïve patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 336-339.
[13]	Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.
[14]	Wang Yunyun, Wu Wanfeng, Li Li. Antiviral efficacy and impact on blood glucose control of direct acting antivirals in treatment of patients with genotype 1b chronic hepatitis C and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2023, 26(3): 344-347.
[15]	Xu Haimiao, Zheng Ruiqi, Ding Huiguo. Short-term efficacy of pitavastatin and polyene phosphatidyl choline combination in the treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 352-355.